Medicenna Therapeutics Income Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 30, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Selling, General & Admin	5.86	5.96	7.87	7	7.76	6.53
Research & Development	15.87	14.44	10.8	9.3	14.72	10.87
Total Operating Expenses	21.73	20.41	18.67	16.3	22.47	17.4
Operating Income	-21.73	-20.41	-18.67	-16.3	-22.47	-17.4
Interest Income	1.22	1.35	1.2	0.91	0.07	0.31
Other Non-Operating Income (Expense)	-16.56	-14.04	14.64	-9.61	-0.07	-0.31
Total Non-Operating Income (Expense)	-15.33	-12.69	15.84	-8.69	0	0
Pretax Income	-37.06	-33.1	-2.83	-25	-22.47	-17.4
Net Income	-13.1	-11.81	-25.47	-10.05	-22.58	-17.29
Net Income to Common	-13.1	-11.81	-25.47	-10.05	-22.58	-17.29
Shares Outstanding (Basic)	79	77	70	65	54	50
Shares Outstanding (Diluted)	79	77	70	65	54	50
Shares Change (YoY)	2.51%	10.10%	7.57%	19.25%	9.31%	55.68%
EPS (Basic)	-0.16	-0.15	-0.37	-0.16	-0.42	-0.35
EPS (Diluted)	-0.16	-0.15	-0.37	-0.16	-0.42	-0.35
Shares Outstanding	83.42	78.22	69.64	69.64	55.65	53.55
Free Cash Flow	-17.71	-16.53	-16.26	-12.66	-23.58	-15.31
Free Cash Flow Per Share	-0.22	-0.22	-0.23	-0.20	-0.43	-0.31
EBITDA	-21.66	-20.35	-18.67	-16.3	-22.44	-17.36
EBIT	-21.73	-20.41	-18.67	-16.3	-22.47	-17.4

Updated Mar 30, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.